IBCN 2017: Bladder Cancer Pipeline- TARIS Technology Update in Urothelial Carcinoma

Lisbon, Portugal (UroToday.com) Christopher Cutie from TARIS technology provided an update of future targeted agents. TAR-200 is an intravesical chemoimmunotherapy platform which a drug core can be fitted into a retentive nitonol frame catheter. The drug is water soluble and can release over 90 days. Using a rat intravesical perfusion tumor model to make reproducible results using this system. Chemotherapy agents include gemcitabine which is well tolerated and continuous delivery maxims therapeutic efficacy. Prior results shows deposition across all layers of the bladder in rat and pig models. Dosing is approximately 20mg Gemcitabine or 1% of standard intravenous dosing. GemRIS is a phase 1b study with 2 seven day periods of treatment with 7 days of rest in between. Objective response rate was 40% with complete response (pT0) 10% and minimal toxicity. Interestingly, further molecular characterization demonstrated a profound immune response with significant reduction in T regulatory to T effector ratio in CD8 in tumor microenvironment. Further study discerning role in control of metastatic disease is underway.

Speaker(s): Christopher Cutie, TARIS technology

Written by: Stephen B. Williams, M.D., Associate Professor, Division of Urology, The University of Texas Medical Branch, Galveston, TX. and Ashish M. Kamat, M.D. Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX., at the International Bladder Cancer Network - October 21, 2017- Lisbon, Portugal

Login